SABCS 2021
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
SABCS 2021
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
CHEST 2020
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.